The opioid use disorder treatment market, at a 7.25% CAGR, is anticipated to reach USD 11.545 billion in 2031 from USD 7.588 billion in 2025.
The opioid use disorder (OUD) treatment market is expanding steadily, propelled by the escalating clinical and societal burden of opioid dependence characterized by compulsive use, high relapse risk, and potential for fatal overdose. Medication for opioid use disorder (MOUD) - methadone, buprenorphine, and naltrexone - constitutes the evidence-based foundation of therapy, with behavioral counseling and peer-support models serving as critical adjuncts that improve retention and long-term outcomes.
Primary demand drivers remain rooted in the widespread medical use of opioids for chronic pain associated with cancer, cardiovascular disease, orthopedic conditions, post-surgical recovery, and trauma. Prolonged exposure, even when clinically indicated, frequently transitions legitimate prescribing into dependence and withdrawal syndromes upon dose reduction or cessation, sustaining a large and growing treatment-eligible population.
Structural reforms in the United States have significantly broadened access to MOUD and are expected to accelerate market growth throughout the forecast period. The elimination of the DATA-2000 waiver and removal of patient caps on buprenorphine prescribing have removed longstanding barriers, enabling a far wider range of practitioners to initiate and maintain therapy. Expanded Medicare and state Medicaid coverage of comprehensive opioid treatment programs (OTPs) - reimbursed through bundled services under code H0020 that include methadone administration, toxicology screening, nursing, and counseling - further lowers financial hurdles. Notably, Medicaid already finances care for approximately 40% of non-elderly adults with OUD in the U.S.
Integration of evidence-based psychosocial interventions continues to gain traction. Narcotics Anonymous, Alcoholics Anonymous, motivational enhancement, and structured counseling are increasingly embedded within inpatient and outpatient programs, helping patients reframe opioid use, strengthen relapse-prevention skills, and build recovery-oriented behavioral repertoires.
North America is projected to maintain clear market leadership, driven by high prevalence of chronic pain conditions, elevated rates of opioid prescribing for both malignant and non-malignant pain, and concentrated commercial presence of major manufacturers. Companies such as Indivior derive the majority of revenue from the U.S. market, reflecting both disease burden and favorable reimbursement dynamics.
Innovation remains focused on formulations that enhance adherence, reduce diversion, and simplify administration. A landmark regulatory advancement occurred in May 2023 when the FDA accepted Braeburn’s revised New Drug Application for BRIXADI (buprenorphine) extended-release subcutaneous injection (weekly and monthly dosing) for moderate to severe OUD. Approval and subsequent launch of long-acting injectable buprenorphine formulations are anticipated to shift treatment paradigms, particularly in populations with poor oral medication adherence.
Competitive activity centers on next-generation delivery systems, combination pharmacotherapies, and digital therapeutic adjuncts designed to reinforce behavioral change. Leading developers, including Braeburn Pharmaceuticals, continue to advance candidates that address unmet needs in induction, stabilization, and maintenance phases.
In conclusion, the OUD treatment sector is poised for sustained expansion, supported by irreversible regulatory liberalization, comprehensive public insurance coverage of OTP services, and persistent clinical need generated by medical opioid exposure. North America will continue to dominate both in market size and therapeutic innovation, with long-acting injectable buprenorphine formulations such as BRIXADI representing the most significant recent advancement in expanding safe, effective, and accessible MOUD options for patients with moderate to severe opioid use disorder.
The opioid use disorder (OUD) treatment market is expanding steadily, propelled by the escalating clinical and societal burden of opioid dependence characterized by compulsive use, high relapse risk, and potential for fatal overdose. Medication for opioid use disorder (MOUD) - methadone, buprenorphine, and naltrexone - constitutes the evidence-based foundation of therapy, with behavioral counseling and peer-support models serving as critical adjuncts that improve retention and long-term outcomes.
Primary demand drivers remain rooted in the widespread medical use of opioids for chronic pain associated with cancer, cardiovascular disease, orthopedic conditions, post-surgical recovery, and trauma. Prolonged exposure, even when clinically indicated, frequently transitions legitimate prescribing into dependence and withdrawal syndromes upon dose reduction or cessation, sustaining a large and growing treatment-eligible population.
Structural reforms in the United States have significantly broadened access to MOUD and are expected to accelerate market growth throughout the forecast period. The elimination of the DATA-2000 waiver and removal of patient caps on buprenorphine prescribing have removed longstanding barriers, enabling a far wider range of practitioners to initiate and maintain therapy. Expanded Medicare and state Medicaid coverage of comprehensive opioid treatment programs (OTPs) - reimbursed through bundled services under code H0020 that include methadone administration, toxicology screening, nursing, and counseling - further lowers financial hurdles. Notably, Medicaid already finances care for approximately 40% of non-elderly adults with OUD in the U.S.
Integration of evidence-based psychosocial interventions continues to gain traction. Narcotics Anonymous, Alcoholics Anonymous, motivational enhancement, and structured counseling are increasingly embedded within inpatient and outpatient programs, helping patients reframe opioid use, strengthen relapse-prevention skills, and build recovery-oriented behavioral repertoires.
North America is projected to maintain clear market leadership, driven by high prevalence of chronic pain conditions, elevated rates of opioid prescribing for both malignant and non-malignant pain, and concentrated commercial presence of major manufacturers. Companies such as Indivior derive the majority of revenue from the U.S. market, reflecting both disease burden and favorable reimbursement dynamics.
Innovation remains focused on formulations that enhance adherence, reduce diversion, and simplify administration. A landmark regulatory advancement occurred in May 2023 when the FDA accepted Braeburn’s revised New Drug Application for BRIXADI (buprenorphine) extended-release subcutaneous injection (weekly and monthly dosing) for moderate to severe OUD. Approval and subsequent launch of long-acting injectable buprenorphine formulations are anticipated to shift treatment paradigms, particularly in populations with poor oral medication adherence.
Competitive activity centers on next-generation delivery systems, combination pharmacotherapies, and digital therapeutic adjuncts designed to reinforce behavioral change. Leading developers, including Braeburn Pharmaceuticals, continue to advance candidates that address unmet needs in induction, stabilization, and maintenance phases.
In conclusion, the OUD treatment sector is poised for sustained expansion, supported by irreversible regulatory liberalization, comprehensive public insurance coverage of OTP services, and persistent clinical need generated by medical opioid exposure. North America will continue to dominate both in market size and therapeutic innovation, with long-acting injectable buprenorphine formulations such as BRIXADI representing the most significant recent advancement in expanding safe, effective, and accessible MOUD options for patients with moderate to severe opioid use disorder.
Key Benefits of this Report:
- Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
- Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
- Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
- Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
- Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.
What can this report be used for?
Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence.Report Coverage:
- Historical data from 2021 to 2025 & forecast data from 2026 to 2031
- Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
- Competitive Positioning, Strategies, and Market Share Analysis
- Revenue Growth and Forecast Assessment of segments and regions including countries
- Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.
Opioid Use Disorder Treatment Market Segmentation:
BY TREATMENT TYPE
- Medication
- Buprenorphine
- Methadone
- Naltrexone
- Counseling & Behavioral Therapies
BY ROUTE OF ADMINISTRATION
- Oral
- Injectable
BY END-USER
- Rehabilitation Centers
- Specialized Clinics
- Others
BY GEOGRAPHY
- North America
- USA
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Others
- Europe
- Germany
- France
- United Kingdom
- Spain
- Others
- Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Others
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Thailand
- Others
Table of Contents
1. EXECUTIVE SUMMARY4. TECHNOLOGICAL OUTLOOK
2. MARKET SNAPSHOT
3. BUSINESS LANDSCAPE
5. OPIOID USE DISORDER TREATMENT MARKET BY TREATMENT TYPE
6. OPIOID USE DISORDER TREATMENT MARKET BY ROUTE OF ADMINISTRATION
7. OPIOID USE DISORDER TREATMENT MARKET BY END-USER
8. OPIOID USE DISORDER TREATMENT MARKET BY GEOGRAPHY
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
10. COMPANY PROFILES
11. APPENDIX
Companies Mentioned
The companies profiled in this Opioid Use Disorder Treatment market report include:- Indivior Plc
- Alkermes Plc
- Orexo AB
- Titan Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
- Mallinckrodt Pharmaceuticals
- Pfizer Inc.
- Hikma Pharmaceuticals PLC
- Camurus
- Collegium Pharmaceuticals
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | January 2026 |
| Forecast Period | 2025 - 2031 |
| Estimated Market Value ( USD | $ 7.59 Billion |
| Forecasted Market Value ( USD | $ 11.55 Billion |
| Compound Annual Growth Rate | 7.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
